Biomedical research institute
    You are here: Home / Departments / Infection, Immunity and Inflammation / Team A. Hosmalin, R. Cheynier

    Team : Dendritic cells, B lymphocytes and cytokines in their microenvironment during viral infections and cancer

    Team leaders





    Dendritic cells (DC) integrate signals from the microenvironment and govern immune polarization. They are the only cells able to present antigens to naive T lymphocytes and they are the main producers of type I interferons (IFN-I) in response to viruses. Therefore they are crucial for innate immunity, adaptive immunity and tolerance.


    Our team studies antigen presentation by DC. It has demonstrated cross-presentation ability of  human plasmacytoid DC (pDC) and conventional DC1 bearing the chemokine receptor XCR1. We showed that DC perform cross-presentation of HIV antigens to specific CD8+ T lymphocytes specific for HIV very efficiently not only from apoptotic infected cells, but also from live cells. We are seeking to exploit this antigen presentation from live cells to kill cells which are HIV reservoirs or, with Armelle Prévost-Blondel, metastatic melanoma cells.  (Immune activation and suppression during HIV infecton)

    We study the roles of different DC and monocyte/macrophage populations in T cell response polarization et in  type I or III IFN production during HIV infection.  We were the first to show during this infection the depletion of circulating DC et the accumulation of pro-inflammatory slan+ monocytes. Our aim is to reduce the reservoirs and the immune hyper activation and immune suppression which are linked to this chronic viral infection.(Immune activation and suppression during HIV infecton)

    Armelle Prévost-Blondel, a tumor immunology expert, joined the team in 2016. She focuses on the suppression of immune responses to melanoma by Phenylalanine oxidase IL4i1 (IL4-induced gene 1). She recently showed with Yolande Richard a regulatory role of IL4i1 on B lymphocytes. She studies the mechanism and the impact of this regulation in general, and specifically during the development of melanoma. Her aim is to improve the efficacy of therapies in patients suffering from metastatic melanoma. 

    POST-DOC OFFER (already funded by INCA) in ONCO-IMMUNOLOGY




    Departement Teams